BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

July 10, 2023 | News

Meissa Vaccines Signs CGMP Manufacturing Agreement for Pediatric RSV Vaccine in Phase 2 Trials

Under the agreement, Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under Current Good Manufacturing Practice (CGMP) regulations to ...

July 06, 2023 | News

China NMPA approves RareStone's pitolisant (Wakix) for the treatment of narcolepsy

RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chi...

July 05, 2023 | News

FDA Approves Cu-64 SAR-bisPSMA Phase III Trial for Prostate Cancer

FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...

July 05, 2023 | News

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

The pivotal clinical trial approved in China will evaluate the efficacy and safety of Glecirasib as a single agent for the second line treatment ...

July 05, 2023 | News

Innovent and IASO Bio Receive NMPA Approval for FUCASO®, a Fully-human BCMA CAR-T Therapy for Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

July 03, 2023 | News

Promising Clinical Trial Data for Migraine Treatment: CER-0001, a Ketogenic Investigational Agent

A poster showcasing data from the RELIEF study of CER-0001 (tricaprilin), being investigated for the preventive treatment of migraine, was presented at t...

July 03, 2023 | News

Bioheart announces clinical result for Iberis-HTN at CIT 2023

Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode...

June 30, 2023 | News

AI-Designed Drug Enters Phase II Trials, First Patients Dosed by Insilico Medicine

After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has ent...

June 28, 2023 | News

Innovent and RemeGen Collaborate on Clinical Trial for Combined Therapy of TYVYT® and Novel ADCs in China

Under the agreement, Innovent will provide clinical drug supplies of TYVYT® (sintilimab injection) during the clinical trial collaboration. RemeGen wil...

June 26, 2023 | News

Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharmaceuticals to Develop a Novel Cancer Therapeutic

The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The licen...

June 23, 2023 | News

Everest Medicines' Partner Calliditas Presents Nefecon Data at ERA-EDTA Congress

The presentations showed data and analyses from the NefIgArd Phase 3 clinical trial evaluating Nefecon in patients with IgA nephropathy (IgAN). The study m...

June 21, 2023 | News

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase...

June 21, 2023 | News

Sirnaomics Advances STP705 for SCCIS into Late-Stage Clinical Development

The FDA provided Sirnaomics guidance to move forward with late-stage clinical development because of the efficacious data provided as well as the widesprea...

June 20, 2023 | News

Stay Connected